360-OR: Hyperglucagonemia Reduces De Novo Lipogenesis and Increases Gluconeogenesis in Healthy Subjects
Although the effect of glucagon on glucose metabolism has been well characterized, its effect on lipid metabolism, particularly lipolysis and de novo lipogenesis, in humans in vivo has been poorly studied with controversial results. We examined the effect of short-term hyperglucagonemia on de novo l...
Saved in:
Published in | Diabetes (New York, N.Y.) Vol. 71; no. Supplement_1 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
American Diabetes Association
01.06.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 0012-1797 1939-327X |
DOI | 10.2337/db22-360-OR |
Cover
Loading…
Abstract | Although the effect of glucagon on glucose metabolism has been well characterized, its effect on lipid metabolism, particularly lipolysis and de novo lipogenesis, in humans in vivo has been poorly studied with controversial results. We examined the effect of short-term hyperglucagonemia on de novo lipogenesis (DNL) and endogenous glucose production (EGP) in 8 healthy normal glucose tolerant subjects (5M/3F, age=35±5, BMI= 24±1) who received a 12-hour (6PM to 6AM) glucagon infusion (6ng/kg/min) infusion with measurement of EGP (3-3H-glucose) on the following morning 6-AM. Subjects received deuterated water (D2O, 5g/kg fat free mass) at PM on the night prior to study. 8 weeks later subjects returned for a repeat study with 12-hour infusion of normal saline. DNL was quantified by measuring the incorporation of deuterated water into circulating triglycerides. Gluconeogenic rate was measured as (EGP) x (plasma C5/C2 glucose ratio) (EGP) x (plasma C5/C2 glucose ratio) . Plasma esterified and non-esterified FFA levels were measured with gas chromatography mass spectrometry (GC-MS) . Plasma glucagon increased from 57±3 to 219±21 pg/ml within one hour and remained elevated throughout the study. DNL was significantly decreased (1.64 ± 0.58% vs. 3.± 0.98%, p<0.05) after glucagon versus saline infusion. Both plasma palmitate (0.73 ± 0.vs. 0.67 ± 0.mmol/L) and total FFA (1.35 ± 0.vs. 1.21 ±0.mmol/L) concentrations were elevated after glucagon infusion (p<0.05) . EGP increased following glucagon infusion (2.13 ± 0.14 vs. 1.97± 0.11mg/kg/min, p =0.006) . The increase in EGP was primarily due to increased gluconeogenesis (1.48 ± 0.14 vs. 1.27 ± 0.11, p=0.02) , while the rate of glycogenolysis did not change (0.65± 0.14 vs. 0.70± 0.11, p=ns) . Conclusion: Short-term (12-hour) physiologic hyperglucagonemia in healthy subjects reduces hepatic de novo lipogenesis, stimulates adipose tissue lipolysis, and increases hepatic glucose production by increasing gluconeogenesis. |
---|---|
AbstractList | Although the effect of glucagon on glucose metabolism has been well characterized, its effect on lipid metabolism, particularly lipolysis and de novo lipogenesis, in humans in vivo has been poorly studied with controversial results. We examined the effect of short-term hyperglucagonemia on de novo lipogenesis (DNL) and endogenous glucose production (EGP) in 8 healthy normal glucose tolerant subjects (5M/3F, age=35±5, BMI= 24±1) who received a 12-hour (6PM to 6AM) glucagon infusion (6ng/kg/min) infusion with measurement of EGP (3-3H-glucose) on the following morning 6-AM. Subjects received deuterated water (D2O, 5g/kg fat free mass) at PM on the night prior to study. 8 weeks later subjects returned for a repeat study with 12-hour infusion of normal saline. DNL was quantified by measuring the incorporation of deuterated water into circulating triglycerides. Gluconeogenic rate was measured as (EGP) x (plasma C5/C2 glucose ratio) (EGP) x (plasma C5/C2 glucose ratio) . Plasma esterified and non-esterified FFA levels were measured with gas chromatography mass spectrometry (GC-MS) . Plasma glucagon increased from 57±3 to 219±21 pg/ml within one hour and remained elevated throughout the study. DNL was significantly decreased (1.64 ± 0.58% vs. 3.± 0.98%, p<0.05) after glucagon versus saline infusion. Both plasma palmitate (0.73 ± 0.vs. 0.67 ± 0.mmol/L) and total FFA (1.35 ± 0.vs. 1.21 ±0.mmol/L) concentrations were elevated after glucagon infusion (p<0.05) . EGP increased following glucagon infusion (2.13 ± 0.14 vs. 1.97± 0.11mg/kg/min, p =0.006) . The increase in EGP was primarily due to increased gluconeogenesis (1.48 ± 0.14 vs. 1.27 ± 0.11, p=0.02) , while the rate of glycogenolysis did not change (0.65± 0.14 vs. 0.70± 0.11, p=ns) . Conclusion: Short-term (12-hour) physiologic hyperglucagonemia in healthy subjects reduces hepatic de novo lipogenesis, stimulates adipose tissue lipolysis, and increases hepatic glucose production by increasing gluconeogenesis. |
Author | CIOCIARO, DEMETRIO MOCCIARO, GABRIELE GASTALDELLI, AMALIA PEZZICA, SAMANTHA CARLI, FABRIZIA TRIPATHY, DEVJIT CHEN, XI DEFRONZO, RALPH A. |
Author_xml | – sequence: 1 givenname: XI surname: CHEN fullname: CHEN, XI – sequence: 2 givenname: FABRIZIA surname: CARLI fullname: CARLI, FABRIZIA – sequence: 3 givenname: SAMANTHA surname: PEZZICA fullname: PEZZICA, SAMANTHA – sequence: 4 givenname: GABRIELE surname: MOCCIARO fullname: MOCCIARO, GABRIELE – sequence: 5 givenname: DEMETRIO surname: CIOCIARO fullname: CIOCIARO, DEMETRIO – sequence: 6 givenname: AMALIA surname: GASTALDELLI fullname: GASTALDELLI, AMALIA – sequence: 7 givenname: RALPH A. surname: DEFRONZO fullname: DEFRONZO, RALPH A. – sequence: 8 givenname: DEVJIT surname: TRIPATHY fullname: TRIPATHY, DEVJIT |
BookMark | eNo9kMFKw0AQhhepYFs9-QILHiU6u5tsEm9StS0EC60Hb8skmcSUNom7jdC3d0tF5jCH-f5_4JuwUdu1xNitgAepVPxY5lIGSkOwWl-wsUhVGigZf47YGEDIQMRpfMUmzm0BQPsZs_pMP_HFsSdb74YCa9-5b5CvqRwKcvyF-Hv30_Gs6buaWnKN49iWfNkWltB5Yu5jPvR_bVq-INwdvo58M-RbKg7uml1WuHN087enbPP2-jFbBNlqvpw9Z0GhQwjKqBIyBZWoCASCQtClFlLlGnWVSIkqpTKKSi1RhAoxrKRGkRLkSaGFVlN2d27tbfc9kDuYbTfY1j80UidRlIYJgKfuz1RhO-csVaa3zR7t0QgwJ4_m5NF4M2a1Vr9DZ2ai |
ContentType | Journal Article |
Copyright | Copyright American Diabetes Association Jun 2022 |
Copyright_xml | – notice: Copyright American Diabetes Association Jun 2022 |
DBID | AAYXX CITATION K9. NAPCQ |
DOI | 10.2337/db22-360-OR |
DatabaseName | CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium |
DatabaseTitle | CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1939-327X |
ExternalDocumentID | 10_2337_db22_360_OR |
Genre | Conference Proceeding |
GroupedDBID | --- .55 .XZ 08P 0R~ 18M 29F 2WC 354 4.4 53G 5GY 5RE 5RS 5VS 6PF 8R4 8R5 AAFWJ AAQQT AAWTL AAYEP AAYXX ABOCM ACGFO ACGOD ACPRK ADBBV AEGXH AENEX AERZD AHMBA AIAGR AIZAD ALIPV ALMA_UNASSIGNED_HOLDINGS BAWUL BES BTFSW CITATION CS3 DIK DU5 E3Z EBS EDB EMOBN EX3 F5P FRP GX1 H13 HZ~ IAO IEA IHR INH INR IOF IPO K2M KQ8 L7B M5~ O5R O5S O9- OHH OK1 OVD P2P PCD Q2X RHI RPM SJN SV3 TDI TEORI TR2 VVN W8F WH7 WOQ WOW X7M YFH YHG YOC ZY1 ~KM K9. NAPCQ |
ID | FETCH-LOGICAL-c640-d5f1290383501a03a06d6123b6a6f822a39ed55d62a143aa4f26a19e0b8c6163 |
ISSN | 0012-1797 |
IngestDate | Mon Jun 30 10:42:36 EDT 2025 Tue Jul 01 02:41:20 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement_1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c640-d5f1290383501a03a06d6123b6a6f822a39ed55d62a143aa4f26a19e0b8c6163 |
Notes | ObjectType-Conference Proceeding-1 SourceType-Scholarly Journals-1 content type line 14 |
PQID | 2685594800 |
PQPubID | 34443 |
ParticipantIDs | proquest_journals_2685594800 crossref_primary_10_2337_db22_360_OR |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-06-01 20220601 |
PublicationDateYYYYMMDD | 2022-06-01 |
PublicationDate_xml | – month: 06 year: 2022 text: 2022-06-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | New York |
PublicationPlace_xml | – name: New York |
PublicationTitle | Diabetes (New York, N.Y.) |
PublicationYear | 2022 |
Publisher | American Diabetes Association |
Publisher_xml | – name: American Diabetes Association |
SSID | ssj0006060 |
Score | 2.3914666 |
Snippet | Although the effect of glucagon on glucose metabolism has been well characterized, its effect on lipid metabolism, particularly lipolysis and de novo... |
SourceID | proquest crossref |
SourceType | Aggregation Database Index Database |
SubjectTerms | Adipose tissue Diabetes Gas chromatography Glucagon Gluconeogenesis Glucose Glucose metabolism Lipid metabolism Lipogenesis Lipolysis Liver Mass spectroscopy Metabolism Palmitic acid Plasma Triglycerides |
Title | 360-OR: Hyperglucagonemia Reduces De Novo Lipogenesis and Increases Gluconeogenesis in Healthy Subjects |
URI | https://www.proquest.com/docview/2685594800 |
Volume | 71 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgkRAXxFMsLMiHvaFAnnbCLaSFBGiLQpGqXiI7caoeNl1tuxz49cw4TpotPSxcoijpOJXny_ibycyYkHMgbCoMJbMcGbiWrzizIuVLS1XSEcJ1ea2b-kymLP3pf1kEi31MV1eX7OS78vfRupL_0SpcA71ilew_aLYfFC7AOegXjqBhON5Kxx6zrVmOTn0K7uQVpp-L1aZRF2sB81ZdY7bVSL2dbn5twPm-3KzQsK23JgcY-eIWfvEZs9Yb1d_V3a8wK0ybFYzTbIcUdjSI1h7u4zOIKyTpWGcQLPqwbBLn3zJNluOPebbMeux8Hy-XWRLrQCysAdN52t-azJIki_OZDt-j2Ng0DjGBCvBx-4Sqzvg6LnZD5UPjy50ByPRGpjoqWjjHzLvr6QYBlcQKBD3D-1Ws-3J_sLj1KYfg7KB4gcIFCBez_C655wJWcd-LUfa1X7_BpWsLl8zfbas6Ufj94Mk3eczNZVxzk_kj8tA4FTRuEfKY3FHNE3J_YtImnpJVO9gH-hdMqIEJHSmKMKEDmFCACe1hQg9gQtcNNTChHUyekR-fxvMktcwOG1bJfNuqghrDkF6IX5eF7QmbVdiORzLBamCOwotUFQQVcwXQaiH82mXCiZQtw5IBkX9OThp48AtCpc05r8tK-bzyy6AMgReXNXhvMmJRHfBTct7NVnHZtlEpjmjklJx1M1mY92xbuCwMsKmQbb-83SivyIM9_s7Iye7qWr0G6riTb7Sm_wCtu2lf |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=360-OR%3A+Hyperglucagonemia+Reduces+De+Novo+Lipogenesis+and+Increases+Gluconeogenesis+in+Healthy+Subjects&rft.jtitle=Diabetes+%28New+York%2C+N.Y.%29&rft.au=CHEN%2C+XI&rft.au=CARLI%2C+FABRIZIA&rft.au=PEZZICA%2C+SAMANTHA&rft.au=MOCCIARO%2C+GABRIELE&rft.date=2022-06-01&rft.issn=0012-1797&rft.volume=71&rft.issue=Supplement_1&rft_id=info:doi/10.2337%2Fdb22-360-OR&rft.externalDBID=n%2Fa&rft.externalDocID=10_2337_db22_360_OR |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-1797&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-1797&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-1797&client=summon |